Effect of Dupilumab an mucus plugs and inflammatory patterns in sEvere asThmAtiC paTients — a Pilot Study (DETACT)

Status

Recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517567-23-00

Acronym

DETACT

Enrollment

Registered

2024-12-10

Start date

2023-02-02

Completion date

Unknown

Last updated

2024-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe asthma

Brief summary

To evaluate the effect of Dupilumab on mucus plugging in the airways of patients suffering from severe asthma

Interventions

DRUGDupixent 300 mg solution for injection in pre-filled syringe

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
To evaluate the effect of Dupilumab on mucus plugging in the airways of patients suffering from severe asthma	—

Countries

Austria

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026